Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era

Savino Bruno, Alessandra Mangia

Research output: Contribution to journalArticlepeer-review

Abstract

Two first-generation non-specific protein 3/4A protease inhibitors (Boceprevir and Telaprevir) have been approved in the U.S. and in Europe in combination with the standard of care for treatment of both previously untreated and prior non responder genotype 1 chronic hepatitis C, based on the results of 5 large phase III trials. With these drugs, futility-stopping rules at weeks 4, 8 and 12 have been provided in order to avoid ineffective therapy and dangerous adverse events. However, despite several guidelines that have been published, a main question remains: how we can identify patients in whom triple therapy will be useless or ineffective? Based on the available data, this review proposes three algorithms to optimize triple antiviral therapy for chronic hepatitis C, to aid physicians avoid prescription of unnecessary treatment, given its substantial side effects and costs.

Original languageEnglish
Pages (from-to)356-361
Number of pages6
JournalDigestive and Liver Disease
Volume45
Issue number5
DOIs
Publication statusPublished - May 2013

Keywords

  • DAA
  • First generation of protease inhibitors
  • HCV treatment

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era'. Together they form a unique fingerprint.

Cite this